McKesson Corporation (MCK) - Total Assets
Based on the latest financial reports, McKesson Corporation (MCK) holds total assets worth $88.33 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
McKesson Corporation - Total Assets Trend (1995–2026)
This chart illustrates how McKesson Corporation's total assets have evolved over time, based on quarterly financial data. Also see McKesson Corporation (MCK) market capitalisation for the company's overall valuation and market capitalisation.
McKesson Corporation - Asset Composition Analysis
Current Asset Composition (March 2026)
McKesson Corporation's total assets of $88.33 Billion consist of 69.5% current assets and 30.5% non-current assets. Review McKesson Corporation (MCK) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.8% |
| Accounts Receivable | $27.98 Billion | 34.0% |
| Inventory | $24.21 Billion | 29.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.08 Billion | 5.0% |
| Goodwill | $11.32 Billion | 13.8% |
Asset Composition Trend (1995–2026)
This chart illustrates how McKesson Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for McKesson Corporation for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: McKesson Corporation's current assets represent 69.5% of total assets in 2026, a decrease from 77.6% in 1995.
- Cash Position: Cash and equivalents constituted 4.8% of total assets in 2026, down from 11.1% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 6.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 34.0% of total assets.
McKesson Corporation Competitors by Total Assets
Key competitors of McKesson Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998
|
China | CN¥112.28 Billion |
|
TELES Informationstechnologien AG
XETRA:TLIK
|
Germany | €4.29 Million |
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$8.80 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
|
Brazil | R$5.64 Billion |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
|
China | CN¥235.37 Billion |
McKesson Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.89 | 0.88 | 0.99 |
| Quick Ratio | 0.52 | 0.49 | 0.57 |
| Cash Ratio | 0.00 | 0.04 | 0.05 |
| Working Capital | $-7.52 Billion | $-7.53 Billion | $-495.00 Million |
McKesson Corporation - Advanced Valuation Insights
This section examines the relationship between McKesson Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.04 |
| Latest Market Cap to Assets Ratio | 1.23 |
| Asset Growth Rate (YoY) | 9.6% |
| Total Assets | $82.32 Billion |
| Market Capitalization | $101.38 Billion USD |
Valuation Analysis
Above Book Valuation: The market values McKesson Corporation's assets above their book value (1.23x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: McKesson Corporation's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for McKesson Corporation (1995–2026)
The table below shows the annual total assets of McKesson Corporation from 1995 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $82.32 Billion | +9.56% |
| 2025-03-31 | $75.14 Billion | +11.41% |
| 2024-03-31 | $67.44 Billion | +8.22% |
| 2023-03-31 | $62.32 Billion | -1.55% |
| 2022-03-31 | $63.30 Billion | -2.64% |
| 2021-03-31 | $65.02 Billion | +6.15% |
| 2020-03-31 | $61.25 Billion | +2.64% |
| 2019-03-31 | $59.67 Billion | -1.17% |
| 2018-03-31 | $60.38 Billion | -0.96% |
| 2017-03-31 | $60.97 Billion | +7.79% |
| 2016-03-31 | $56.56 Billion | +5.00% |
| 2015-03-31 | $53.87 Billion | +4.08% |
| 2014-03-31 | $51.76 Billion | +48.79% |
| 2013-03-31 | $34.79 Billion | +5.12% |
| 2012-03-31 | $33.09 Billion | +7.15% |
| 2011-03-31 | $30.89 Billion | +9.57% |
| 2010-03-31 | $28.19 Billion | +11.56% |
| 2009-03-31 | $25.27 Billion | +2.70% |
| 2008-03-31 | $24.60 Billion | +2.76% |
| 2007-03-31 | $23.94 Billion | +14.15% |
| 2006-03-31 | $20.98 Billion | +11.72% |
| 2005-03-31 | $18.77 Billion | +15.61% |
| 2004-03-31 | $16.24 Billion | +13.15% |
| 2003-03-31 | $14.35 Billion | +7.73% |
| 2002-03-31 | $13.32 Billion | +15.56% |
| 2001-03-31 | $11.53 Billion | +11.15% |
| 2000-03-31 | $10.37 Billion | +14.22% |
| 1999-03-31 | $9.08 Billion | +61.95% |
| 1998-03-31 | $5.61 Billion | +8.40% |
| 1997-03-31 | $5.17 Billion | +47.63% |
| 1996-03-31 | $3.50 Billion | +0.71% |
| 1995-03-31 | $3.48 Billion | -- |
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; d… Read more